References
- American Academy of Dermatology. Acne Factsheet. Available at: www.aad.org/media/background/factsheets/fact_acne.html Accessed 20 April 2011
- Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008;58:56‐9
- Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999;41:577‐580
- Fried RG, Wechsler A. Psychological problems in the acne patient. Dermatol Ther 2006;19:237‐240
- Koo JY, Smith LL. Psychologic aspects of acne. Pediatr Dermatol 1991;8:185‐188
- Hassan J, Grogan S, Clark-Carter D, et al. The individual health burden of acne: appearance-related distress in male and female adolescents and adults with back, chest and facial acne. J Health Psychol 2009;14:1105‐1118
- Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006;55:490‐500
- Balkrishnan R, Kulkarni AS, Cayce K, et al. Predictors of healthcare outcomes and costs related to medication use in patients with acne in the United States. CUTIS 2006;77:251‐255
- Picardo M, Ottaviani M, Camera E, et al. Sebaceous gland lipids. Dermato-endocrinology 2009;1:68‐71
- Maloney JM, Dietze P Jr., Watson D, et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol 2009;8:837‐844
- Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008;77:249‐256
- YAZ®. (Drospirenone and ethinyl estradiol) Tablets [prescribing information]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc, 2010
- Wessels F, Anderson AN, Kropman K. The cost-effectiveness of isotretinoin in the treatment of acne. Part 3. A cost-minimisation pharmaco-economic model. S Afr Med J 1999;89:791‐794
- Wessels F, Anderson AN, Kropman K. The cost-effectiveness of isotretinoin in the treatment of acne. Part 1. A meta-analysis of effectiveness literature. S Afr Med J 1999;89:780‐784
- Ozolins M, Eady EA, Avery AJ, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 2004;364:2188‐2195
- Ozolins M, Eady EA, Avery A, et al. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Health Technol Assess 2005;9:iii‐212
- Koehler AM, Maibach HI. Electronic monitoring in medication adherence measurement. Implications for dermatology. Am J Clin Dermatol 2001;2:7‐12
- DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200‐209
- Greenlaw SM, Yentzer BA, O'Neill JL, et al. Assessing adherence to dermatology treatments: a review of self-report and electronic measures. Skin Res Technol 2010;16:253‐258
- Yentzer BA, Alikhan A, Teuschler H, et al. An exploratory study of adherence to topical benzoyl peroxide in patients with acne vulgaris. J Am Acad Dermatol 2009;60:879‐880
- Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis 2010;86:103‐108